Concurrent radiotherapy with cisplatin and etoposide for small cell neuroendocrine carcinoma of the cervix

Concurrent radiotherapy with cisplatin and etoposide for small cell neuroendocrine carcinoma of the cervix - EP-CCRT for SCNEC

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003864

Enrollment

Registered

2010-07-05

Start date

2010-12-06

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

small cell neuroendocrine carcinoma of the cervix

Interventions

CCRT CDDP Etoposide

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) Pathologically confirmed neuroendocrine tumors of uterine cervix, stage IB - IVA 2) No prior treatment 3) Age from 20 to 70 4) ECOG PS 0-1 5)Normal organ function WBC >= 3000/mm3 neutrophils >= 1,500/mm3 platelets >= 100,000/mm3 total Bilirubin =<1.5mg/dl BUN =<25mg/dl serum creatinine =<1.2 mg/dl Normal E.C.G 6)No hypersensitivity for CDDP and Etoposide 7)Written informed consent

Exclusion criteria

Exclusion criteria: 1) Patients with severe ischemic heart disease or arrhythmia. 2) Patients with history of myocardial within 6 months 3) Patients with liver cirrhosis 4) Patients with repeat bowel fresh bleeding 5) Patients mental disorder 6) Patients with uncontrollable diabetes 7) Patients with bowel obstruction 8) Patients with active other malignancy 9) Patients which a physician in charge judged not to be eligible

Design outcomes

Primary

Measure	Time frame
Adverse event Feasibility	—

Secondary

Measure	Time frame
Two-year cumulative survival rate Progression-free survival Response rate	—

Countries

Japan

Contacts

Public ContactHirokazu Usui

Chiba University Hospital Department of Gynecology

hirokazu-usui@faculty.chiba-u.jp043-222-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026